Sodium cromoglicate - AZTherapies
Alternative Names: ALZT OP1a; AZT-101; Cromolyn - AZTherapies; Cromolyn sodium - AZTherapies; Sodium cromoglicate inhalant - AZTherapies; Sodium cromoglycate - AZTherapiesLatest Information Update: 28 Sep 2022
At a glance
- Originator AZTherapies
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antihyperglycaemics; Antitussives; Benzopyrans; Chromones; Nootropics; Skin disorder therapies; Small molecules
- Mechanism of Action Glial cell modulators; Mast cell stabilisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Amyotrophic lateral sclerosis
- No development reported Cognition disorders
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for clinical-Phase-Unknown development in Cognition-disorders(Adjuvant therapy) in USA (Inhalation, Powder)
- 28 Sep 2022 AZTherapies re-initiates phase-II clinical trial in Amyotrophic lateral sclerosis (In adults, In the elderly, Treatment-experienced) in USA (Inhalation) (NCT04428775) (AZTherapies pipeline, September 2022)
- 03 Mar 2022 AZTherapies withdrew a phase II trial prior to initiation for Cognition disorders (Adjuvant therapy) in USA (Inhalation) (NCT03202147)